Last $52.13 USD
Change Today +0.09 / 0.17%
Volume 306.4K
LGND On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Frankfurt
OTC US
OTC US
OTC US
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$52.89
Previous Close
$52.04
Day High
$52.89
Day Low
$51.76
52 Week High
02/14/14 - $80.42
52 Week Low
10/9/14 - $41.99
Market Cap
1.0B
Average Volume 10 Days
281.2K
EPS TTM
$0.34
Shares Outstanding
20.0M
EX-Date
04/3/07
P/E TM
152.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

20 Employees
Last Reported Date: 12/1/14
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $500.3K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $294.6K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $368.1K
Vice President, General Counsel and Secretary
Total Annual Compensation: $283.4K
Compensation as of Fiscal Year 2013.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Years 2015, 2016 and 2017

Ligand Pharmaceuticals Incorporated provided earnings guidance for the years 2015, 2016 and 2017. For the year 2015, the company projected revenue to be in the range of $81 million to $83 million, with non-GAAP diluted EPS projected to be in the range of $2.14 to $2.18. Gross margin is projected to be 85%, adjusted cash flow margin is projected to be 60% and adjusted profit margin is projected to be 55%. For the year 2016, revenue is projected to exceed $107 million and non-GAAP diluted EPS is projected to exceed $3.20. For the year 2017, revenue is projected to exceed $146 million and non-GAAP diluted EPS is projected to exceed $4.65.

Ligand Pharmaceuticals Incorporated Announces Consolidated Unaudited Earnings Results for Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter and Reaffirms Earnings Guidance for the Full Year 2014

Ligand Pharmaceuticals Incorporated announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $14,973,000, gain from operations of $3,532,000, income from continuing operations of $777,000 or $0.06 per diluted share, net income of $1,280,000 or $0.06 per diluted share compared to the total revenues of $13,005,000, gain from operations of $3,070,000, income from continuing operations of $1,965,000 or $0.09 per diluted share, net income of $1,965,000 or $0.09 per diluted share for the same quarter a year ago. Non-GAAP income from continuing operations was $7,616,000 or $0.36 per diluted share compared to the $4,151,000 or $0.20 per diluted share for the same quarter year ago. For the nine months period, the company reported total revenues of $41,539,000, gain from operations of $9,989,000, income from continuing operations of $4,160,000 or $0.23 per diluted share, net income of $4,969,000 or $0.23 per diluted share compared to the total revenues of $34,237,000, gain from operations of $8,518,000, income from continuing operations of $6,963,000 or $0.33 per diluted share, net income of $9,551,000 or $0.46 per diluted share for the same period a year ago. Non-GAAP income from continuing operations was $20,128,000 or $0.93 per diluted share compared to $11,554,000 or $0.56 per diluted share for the same period year ago. The company affirmed its previous full-year 2014 financial forecast, the Company expects total revenues to be between $64 million and $66 million, and non-GAAP earnings per diluted share to be between $1.50 and $1.55. For the full year revenue outlook, the company continues to expect that approximately 45% of revenue will be from royalties. The other revenue will be a mix of Captisol material sales and licensing fees. For the fourth quarter of 2014, the company expects total revenues to be between $22.5 million and $24.5 million, and non-GAAP earnings per diluted share to be between $0.57 and $0.62.

Ligand Pharmaceuticals Incorporated - Analyst/Investor Day

To discuss on Ligand's business model and expanding portfolio of partnered and un-partnered assets; the transformation of the Company's financials with expanding operating margins and increasing cash flow; new information about portfolio assets, partners and near-term milestones; highlights of Ligand's research and technologies; overview of lead internal diabetes development program, LGD-6972; financial outlook; and review of tax assets

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $52.13 USD +0.09

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGND.
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 100.0x
Price/Sales 18.9x
Price/Book 23.6x
Price/Cash Flow 149.5x
TEV/Sales 11.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.